TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03210025

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metopa Tab 250mg
Description: Metopa Tab 250mg is manufactured by APT
Study: NCT00579020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin/dexamethasone phosphate ophthalmic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin ophthalmic solution 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone phosphate solution, 0.1%
Study: NCT03701607

Intervention type: OTHER
Intervention: PD-L1 group
Description: PD-L1 expression is evaluated using immunohistochemical assay
Study: NCT04506047

Intervention type: PROCEDURE
Intervention: Percutaneous Coronary Intervention
Description: Percutaneous Coronary Intervention
Study: NCT04347889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Oral loading dose followed by once weekly dosing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Once daily vitamin C 1 gm
Study: NCT03750643

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study: NCT01106235

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Optional correlative studies
Study: NCT01979133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icariin
Description: Participants will receive 20% icariin (100 mg/day) in a commercially available over-the-counter Horny Goat Weed supplement. A dose titration from 100 mg/day to 200 mg/day will be allowed at week 3 participants with less than a 30% reduction in HAMD and/or still using cocaine or alcohol or have a positive urine drug screen. An additional dose titration to 300 mg/day will be allowed at week 6 for participants with less than a 50% reduction in HAMD scores and/or still using cocaine or alcohol or have a positive urine drug screen.
Study: NCT01303198

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: APAP - Therapy
Description: automatic positive pressure therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: APAP - Therapy
Description: automatic positive pressure therapy
Study: NCT00901121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Straumann BoneCeramic
Description: Straumann BoneCeramic (500-1000 microns, 0.5g)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bio-Oss
Description: Bio-Oss spongiosa granules, size of particle 0.25-1 mm
Study: NCT04043078

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: The exercise regime will include daily upper limb aerobic (hand bike) and inspiratory muscle training (POWERbreathe) and upper body strength training every second day until discharge.
Study: NCT00968877

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: capsule 40 000 IU (p.o.) once per week, in 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cholecalciferol
Description: capsule 40 000 IU (p.o.) once per week, in 8 weeks.
Study: NCT00965419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edivoxetine
Description: 0.1 mg/kg/day or participant specific known stable dose, rollover participants (LNBJ \[No NCT number\]) and (LNBF \[NCT00922636\]), up to 0.3 mg/kg/day, oral, daily for up to 5 years.
Study: NCT03322150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Atropine injection (0.01 mg/kg, max 0.5 mg) 3 minutes before spinal anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: Glycopyrrolate (0.00 4mg/kg, max 0.2 mg) 3 minutes before spinal anesthesia
Study: NCT05840536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide plus Chlorothiazide
Description: Patients will receive lasix infusion starting at 5mg/hr along with a bolus dose of chlorothiazide 250mg at the initiation of the protocol. The lasix infusion can be titrated to 10mg after 12hrs based on volume of diuresis. This arm will also receive 250mg bolus doses of chlorothiazide every 12hrs for the duration of the study.~Intravenous (IV) lasix infusion at 5mg/hr plus IV boluses of diuril every 12 hrs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Patients will receive furosemide infusion at 5mg/hr along with an initial bolus dose of furosemide equal to twice their home oral dose. The furosemide infusion can be increased to 10mg/hr after 12hrs based on urine output. This arm will receive bolus doses of furosemide every 12hrs equal to twice their home oral dose until completion of the protocol.
Study: NCT02146885

Intervention type: OTHER
Intervention: Weight Control
Description: Weight Control
Study: NCT00334438

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: rituximab
Description: 250mg/m2, IV, Days 1 and 8

Intervention type: DRUG
Group type: OTHER
Intervention: bortezomib
Description: dose escalation 1.0, 1.3, or 1.5, IVP; Days 4, 8, 11, 15

Intervention type: RADIATION
Group type: OTHER
Intervention: yttrium Y 90 ibritumomab tiuxetan
Description: Dose dependant upon platelet count (0.4mCi/kg) not to exceed 32mCi; Day 8

Intervention type: RADIATION
Group type: OTHER
Intervention: Indium 111 ibritumomab tiuxetan
Description: 5cmCi; IV day 1
Study: NCT00787371

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIntron (peginterferon alfa-2b)
Description: PegIntron 0.25 mcg/kg subcutaneously (SC) once a week (QW) for 12 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIntron (peginterferon alfa-2b)
Description: PegIntron 0.5 mcg/kg SC QW for 12 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIntron (peginterferon alfa-2b)
Description: PegIntron 1.0 mcg/kg subcutaneously (SC) once a week (QW) for 12 weeks
Study: NCT04099576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy and education
Description: Hot-pack, ultrasound, trancutaneus nerve electrical stimulation (TENS) and home program exercises were applied or given to the individuals within the physiotherapy program. In addition to physiotherapy, therapeutic neuroscience education were applied to experimental group. One-to-one speech sessions focusing on pain neurophysiology were organized twice a week for three weeks. Each session lasted 40 minutes. The Therapeutic neuroscience education program included nociception, ion channel neurophysiology, central and peripheral sensitization, methods to help reduce sensitization, neuroplasticity, psychosocial factors involved in the transition from acute pain to chronic pain and behavioral, cognitive responses to pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy alone
Description: Hot-pack, ultrasound, trancutaneus nerve electrical stimulation (TENS) and home program exercises were applied or given to the individuals within the physiotherapy program.
Study: NCT02011789

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Citrus Limonoid Beverage
Description: The limonoid containing beverage will be 12-oz buffered, sterile, orange flavored, artificially sweetened, containing 60 mg vitamin C, 11 mg riboflavin and 250 mg limonin glucoside.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citrus Limonoid Beverage
Description: The limonoid containing beverage will be 12-oz buffered, sterile, orange flavored, artificially sweetened, containing 60 mg vitamin C, 11 mg riboflavin and 250 mg limonin glucoside.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo beverage
Description: The placebo beverage will be 12-oz buffered, sterile, orange flavored, artificially sweetened, containing 60 mg vitamin C and 11 mg riboflavin.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo beverage
Description: The placebo beverage will be 12-oz buffered, sterile, orange flavored, artificially sweetened, containing 60 mg vitamin C and 11 mg riboflavin.
Study: NCT02228850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil
Study: NCT04413175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music therapy
Description: Patients in the music group were provided music therapy that was prepared by the Turkish Psychological Association. They listened to the music that has a calming and relaxing effect for 20 min before and during the procedure.~A portable MP3 player connected to double earphones was used in the present study. After patients took the lithotomy position for cystoscopy, their headphones were inserted and music began to be played. Music was played to the individuals for 20 minutes before and during the procedure. Headphones were removed immediately after the procedure was completed and the double earphones were cleaned with antiseptic solution after each application.
Study: NCT02163850

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct Flow Medical
Description: Direct Flow Medical Transcatheter Aortic Valve Replacement System (TAVR)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Commercially Available
Description: Medtronic CoreValve Transcatheter Aortic Valve Replacement System (TAVR) or Edwards SAPIEN Transcatheter Aortic Valve Replacement System (TAVR)
Study: NCT03595670

Intervention type: OTHER
Intervention: standardized questionnaires
Description: standardized questionnaires concerning the perception

Intervention type: OTHER
Intervention: interview
Description: Semi-directive interviews will be conducted. The purpose of this approach is to question the meaning of the disease (beliefs, representations), the psycho-social management of the disease, its inscription in the socio-cultural condition of the patients.
Study: NCT03075475

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Common Elements Treatment Approach
Description: The Common Elements Treatment Approach (CETA), is a trans-diagnostic psychotherapy that is based on common evidence-based treatments for depression, anxiety, trauma and stress related disorders. This treatment can be used to treat individuals with any of these mental health problems and with any combination of these problems. CETA expands upon traditional treatment approaches that are designed to focus on one specific disorder and has been proven through multiple rigorous trials to reduce the burden of multiple common mental health problems and improve functionality among men and women living in low resource settings. CETA can be provided to people in their own communities by trained and supervised lay providers, for example community health workers.
Study: NCT03137732

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rectus Sheath Catheter
Description: Insertion of rectus sheath catheter via either method

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rectus Sheath Catheter
Description: Insertion of rectus sheath catheter via either method
Study: NCT02751606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferumoxtran-10
Description: ferumoxtran-10 will be administered intravenously one day prior to the MRI scan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7 Tesla MRI
Description: Subjects undergo a 7 Tesla MRI scan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3 Tesla MRI
Description: Subjects undergo a 3 Tesla MRI scan
Study: NCT00887601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3134
Description: Single dose 25 mg (5 x 5 mg) MK3134 capsules in one of the four treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo capsules only in one of the four treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo capsules only in one of the four treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Single dose 5 mg donepezil capsules in two of the four treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3134
Description: Single doses of 1 mg, 5 mg, or 25 mg MK3134 capsules in the assigned treatment periods
Study: NCT03143855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin
Description: Lorcaserin will be administered at a dose of 10 mg twice daily for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered twice daily for for 5 days
Study: NCT03755037

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomid, Respatio and Ethinyl estradiol
Description: Drugs were received during the menstrual cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clomid, Respatio and Ethinyl estradiol
Description: Drugs were received during the menstrual cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomid, Respatio and Ethinyl estradiol
Description: Drugs were received during the menstrual cycle.
Study: NCT00914056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lactulose
Description: withdrawal of lactulose
Study: NCT04021342

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Montmorency tart cherry concentrate
Description: Based on previous analysis done by our laboratory each 60 ml of Montmorency tart cherry concentrate contains approximately 73.5 mg of anthocyanins (cyanidin-3-glucoside equivalents) and 178.8 mg of total phenolics (mean gallic acid equivalents)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo beverage matched for calorie content and visual properties of the cherry concentrate
Study: NCT00578006

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questioners
Description: The investigators will ask you to fill out a brief paper questionnaire periodically to tell us how you are feeling, and how satisfied you are with your care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAR website
Description: You can report your symptoms every time you come to Sloan-Kettering for an appointment or chemotherapy.
Study: NCT03428230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg Paracetamol 3% (1 mL)
Description: Single administration by intrathecal injection just before spinal anaesthesia. The injection will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 mg Paracetamol 3% (2 mL)
Description: Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90 mg Paracetamol 3% (3 mL)
Description: Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
Study: NCT04247256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI Protocol
Description: FOLFIRI standard treatment on day 5 to 7 (both days included) of a 14 day period. repeated bi-weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCO-101
Description: Investigational Medicinal Product, oral tablet administered on day 1 to 6 (both days included) of a 14 day period. repeated bi-weekly
Study: NCT03428230

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, 0.9% saline solution
Description: Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Placebo followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Placebo will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIMP: Chloroprocaine HCl 1% (10 mg/mL), solution for injection
Description: Immediately after intrathecal administration of the Paracetamol dose or Placebo, all patients will receive a single intrathecal dose of Chloroprocaine HCl 1% according to the Summary of Product Characteristics indications. Time interval between the 2 administrations should not exceed 2 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIMP: Chloroprocaine HCl 1% (10 mg/mL), solution for injection
Description: Immediately after intrathecal administration of the Paracetamol dose or Placebo, all patients will receive a single intrathecal dose of Chloroprocaine HCl 1% according to the Summary of Product Characteristics indications. Time interval between the 2 administrations should not exceed 2 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIMP: Chloroprocaine HCl 1% (10 mg/mL), solution for injection
Description: Immediately after intrathecal administration of the Paracetamol dose or Placebo, all patients will receive a single intrathecal dose of Chloroprocaine HCl 1% according to the Summary of Product Characteristics indications. Time interval between the 2 administrations should not exceed 2 min.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NIMP: Chloroprocaine HCl 1% (10 mg/mL), solution for injection
Description: Immediately after intrathecal administration of the Paracetamol dose or Placebo, all patients will receive a single intrathecal dose of Chloroprocaine HCl 1% according to the Summary of Product Characteristics indications. Time interval between the 2 administrations should not exceed 2 min.
Study: NCT00636116

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Crotalinae (pit viper) equine immune F(ab)2
Description: Anavip with Anavip Maintenance Therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Crotalinae (pit viper) equine immune F(ab)2
Description: Anavip with Placebo Maintenance Therapy

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Crotalidae Polyvalent Immune Fab, ovine
Description: CroFab with CroFab Maintenance Therapy
Study: NCT02365311

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transesophageal echocardiography(TEE)
Description: Transesophageal echocardiography examination will be performed TLV in supine and lateral position, 10, 20 and 30 min during OLV in left lateral decubitus position. By using the transesophageal echocardiography, we will evaluate the changes of pulmonary blood flow and cardiac function.
Study: NCT04041648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L606 (Liposomal Treprostinil) Inhalation Solution 51ug
Description: Single ascending dose

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: L606 Inhalation System
Description: Single ascending dose

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: L606 Inhalation System
Description: Single ascending dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Solution
Description: Single ascending dose
Study: NCT03600311

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caloric Restriction
Description: Participants will consume 15 kcal/kg FFM/day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caloric Restriction
Description: Participants will consume 15 kcal/kg FFM/day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Post-Exercise Protein
Description: Participants will ingest 30 g of protein following exercise.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Energy Balance
Description: Participants will consume 40 kcal/kg FFM/day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Post-Exercise Carbohydrate
Description: Participants will ingest 30 g of carbohydrate following exercise.
Study: NCT04112563

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: exploration in white light (WLI)
Description: Exploration of the right colon done in white light (WLI)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: exploration in white light (WLI)
Description: Exploration of the right colon done in white light (WLI)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exploration in LCI
Description: Exploration of the right colon in linked color imaging (LCI)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exploration in LCI
Description: Exploration of the right colon in linked color imaging (LCI)
Study: NCT03397147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Coach Jr.
Description: A brief sleep education program for parents of school-aged children with type 1 diabetes, with a focus on resolving sleep disturbances with parent education and positive bedtime routines.
Study: NCT04304014

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. reuteri
Description: (10\^8 CFU) once a day